Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

204

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

204 results for “CBD”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov40/100

The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy

ClinicalTrials.gov study NCT04672252. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

RCT of CBD for Anxiety in Advanced Breast Cancer

ClinicalTrials.gov study NCT04482244. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
zenodo36/100

Building Envelopes in New York's CBD: Normalized Signed Distance Function Representation

<p>This dataset, developed to substantiate the findings of the study by Zhuang et al. [1], comprises 1,521 building envelopes from the Central Business District (CBD) of New York City (NYC), represented in three formats:&nbsp;the wavefront (obj) format, the Signed Distance Function (SDF) format and 3D binary-volume format.&nbsp;</p> <p>The original mesh data is procured from the NYC Open Data Portal [2]. The process of data manipulation is thoroughly delineated in the referenced research paper [1].</p> <p>[1] Zhuang, X., Ju, Y., Yang, A., &amp; Caldas, L. (2023). Synthesis and Generation for 3D Architecture Volume with Generative Modeling. International Journal of Architecture Computing, AI, Architecture, Accessibility, &amp; Data Justice. DOI: 10.1177/14780771231168233.</p> <p>[2] New York city department of city planning. NYC 3D model by community district, manhattan district, MN05. 2018. Available at: https://www.nyc.gov/site/planning/data-maps/open-data/dwn-nyc-3d-model-download.page. Accessed 15&nbsp;July 2023.</p> <p>&nbsp;</p>

opencc-by-4.0Jul 2023View details →
ClinicalTrials.gov36/100

An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients

ClinicalTrials.gov study NCT01610700. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury

ClinicalTrials.gov study NCT04586712. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

ClinicalTrials.gov study NCT01610713. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Evaluating Microneedling With CBD and Hempseed Oil for Acne Vulgaris Safety and Efficacy

ClinicalTrials.gov study NCT06362889. IPD Sharing: YES. Countries: 1. Publications: 10.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

ClinicalTrials.gov study NCT02224690. IPD Sharing: Not stated. Countries: 3. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

ClinicalTrials.gov study NCT01610687. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Effects of Cannabidiol (CBD) on the Brain

ClinicalTrials.gov study NCT04831294. IPD Sharing: UNDECIDED. Countries: 1. Publications: 13.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV

ClinicalTrials.gov study NCT05209867. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

ClinicalTrials.gov study NCT04754399. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans

ClinicalTrials.gov study NCT02539823. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

ClinicalTrials.gov study NCT02544763. IPD Sharing: Not stated. Countries: 6. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia

ClinicalTrials.gov study NCT05233761. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

University of Alabama at Birmingham (UAB) Adult CBD Program

ClinicalTrials.gov study NCT02700412. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

University of Alabama at Birmingham (UAB) Pediatric CBD Program

ClinicalTrials.gov study NCT02695537. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

ClinicalTrials.gov study NCT02544750. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy

ClinicalTrials.gov study NCT02815540. IPD Sharing: NO. Countries: 1. Publications: 11.

closedIPD-NOFeb 2026View details →
zenodo32/100

Parkinson-CBD

<p>The database includes the raw data of the article &ldquo;Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson&rsquo;s Disease&rdquo; (doi.org/10.3390/ijms22168920). The aim of this study was to evaluate the effects of chronic treatment with cannabidiol (CBD) on Parkinson&rsquo;s disease-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine (6-OHDA) model. Moreover, the potential mechanisms by which CBD exerted its effects in this model has been investigated. The database contains the data obtained by the following evaluations: a) immunohistochemical analysis of the extent of nigrostriatal lesion, b) motor performance assessment by cylinder test (at baseline and after 28days), apomorphine-induced rotation test and rotarod test, c) immunohistochemical analysis of neuroinflammatory response - involving microglia and astrocytes - in the substantia nigra pars compacta, investigating both cell activation and polarization, d)co-localization analysis of transient receptor potential cation channel subfamily V member 1 (TRPV1) and ciliary neurotrophic factor (CNTF) expression in astrocytes.</p> <p>CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibited a preferential action on astrocytes, by activating TRPV1 and enhancing the endogenous neuroprotective response of CNTF. These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent.</p>

opencc-by-4.0Jul 2021View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record